drugset / Trial / NCT00609765
Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors
Phase 2
Terminated
1 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
Open label, single-arm phase II study of avastin combined with fluorouracil, doxorubicin and streptozocin administered in 28-day cycles. Treatment will continue until progression of disease, or until withdrawal due to toxicity, or up to a maximum of 12 cycles (48 weeks). In order to reduce the risk of cardiac toxicity, doxorubicin will be administered for a maximum of 8 cycles. If disease has not progressed after 12 cycles of treatment, avastin monotherapy will continue until disease progression or withdrawal due to toxicity.
Timeline
- Start
- 2007-08
- Primary completion
- 2008-03
- Completion
- 2008-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 40 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 400 mg/m2 | Intravenous |
| Subject | streptozocin | Small molecule | 400 mg/m2 | Intravenous |
| Background | Dexamethasone | Small molecule | 20 mg | Intravenous |
| Background | Ondansetron | Other / unclassified | 16 mg | Intravenous |